Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

[gdpawel]

Precision Therapeutics is in no way abandoning ChemoFx, but looking at BioSpeciFx as a complement to the assay.

They run ChemoFx on a population of tumors, say in breast cancer. They identify the responsive, intermediately responsive, and nonresponsive patients. Then take the molecular markers and find out what these patients have in common with respect to 150 different genes.

Then they work on eliminating the genes that are irrelevant. What they get is a multi-gene predictor. It can't work without ChemoFx working. The BioSpeciFx for breast cancer is accurate 85% of the time according to MD Anderson and US Oncology. Each drug will have it's own signature, but it couldn't happen if ChemoFx wasn't accurate. ChemoFx is the backbone of BioSpeciFx.

The thing that is unique about BioSpeciFx, is that the oncologist can pick and choose which markers he wants to see. An ala carte selection if you will. According to Precision Therapeutics, Caris' Target Now does not do this. In fact, they are running 100-120 different markers, and charging for each one, with relatively no clinical relevancy to justify this.